���景与受体作用机制 — Evidence Review

By Editorial Desk · published 2025-09-01 · last reviewed 2025-09-19 · Topic

This is a working overview of secretagogue, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2025-09-19 and is reviewed periodically as new material appears.

背景与受体作用机制

Ipamorelin 是一种合成五肽，在 20 世纪 90 年代被报道为生长激素促分泌剂。其结构基于胃饥饿素受体激动剂的设计思路，但并非天然激素。早期药理学研究显示，它可刺激垂体释放生长激素，而对应激激素轴的影响相对较小。该化合物常被用作研究生长激素调节通路的工具分子。

在机制层面，ipamorelin 与生长激素促分泌受体 1a 型结合，该受体也介导胃饥饿素的多种效应。受体激活后，细胞内信号促进生长激素从垂体前叶释放。由于对促肾上腺皮质激素和皮质醇的刺激较弱，它被视为选择性较高的促分泌剂。这种选择性在动物模型和少量人体研究中被观察到，但人体数据仍然有限。

Handling, Storage and Analytical Verification

Purity is normally reported as a percentage of total peak area, a figure that does not account for water content, residual solvents, or counterions. Trifluoroacetate and acetate are the most frequent counterions in lyophilized peptides, and they shift the true peptide content away from the mass of the powder. A separate quantitative assay is therefore needed to state content accurately. Certificates of analysis often omit these details, which makes batch-to-batch comparison difficult and limits conclusions drawn when results from different suppliers are compared.

Lyophilized material is generally held at minus twenty degrees Celsius or lower, protected from moisture and light. Repeated excursions to room temperature cause condensation inside the vial and gradual moisture uptake, both of which shorten shelf life. Containers should be allowed to equilibrate before opening so that water does not condense on the solid. Dividing a batch into single-use aliquots reduces freeze-thaw cycling. Solid peptide handled this way is usually considered stable for months to years, while the same material in solution degrades on a much shorter timescale.

Ipamorelin at a glance

Background And Receptor Mechanism

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.

At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.

Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.

Related pages on this site

• Comprehensive trends
• Efficient overview
• Structured summary
• Robust archive
• Standard archive
• Robust report
• Proven dataset
• Connected toolkit

Ipamorelin Background and Pharmacology

At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.

Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.

Supporting material

These increases in coagulation factors may contribute to the development of stroke (see under § Side effects), but a precise association cannot be made at this stage. In a variety of clinical studies upon which FDA approval is based, Neumega showed effectivity in reducing thrombocytopenia in oncologic patients treated with myelosuppressant chemotherapeutic drugs as measured by significantly decreased need of platelet transfusions. Neumega is manufactured and sold by Wyeth. The drug is formulated in single-use vials containing 5 mg of oprelvekin (specific activity approximately 8 million units/mg) as a sterile, lyophilized powder. The FDA approved the drug in 1997.

{\displaystyle Q={\begin{pmatrix}{-(a\pi _{C}+b\pi _{G}+c\pi _{T})}&a\pi _{C}&b\pi _{G}&c\pi _{T}\\a\pi _{A}&{-(a\pi _{A}+d\pi _{G}+e\pi _{T})}&d\pi _{G}&e\pi _{T}\\b\pi _{A}&d\pi _{C}&{-(b\pi _{A}+d\pi _{C}+f\pi _{T})}&f\pi _{T}\\c\pi _{A}&e\pi _{C}&f\pi _{G}&{-(c\pi _{A}+e\pi _{C}+f\pi _{G})}\end{pmatrix}}}

Basilea Pharmaceutica is a biopharmaceutical company based in Allschwil near Basel, Switzerland. Basilea was spun off from F. Hoffmann-La Roche in 2000 and has been listed as an independent company on the Swiss stock exchange since March 2004. The company's subsidiary is Basilea Pharmaceutica International AG, Allschwil, which is also based in Allschwil, Switzerland, and in which the company's operating activities are bundled.

Ultrafiltration is the most hardware demanding option for protein recovery although it serves more as a protein concentration step rather than complete recovery. Chromatographic methods may be used in tandem with ultrafiltration to help increase solute mass and subsequent recovery. Solvent precipitation is not often reported although it produces the highest protein recovery among other methods and preserves the nutritional integrity of the LPC. The extraction and purification methods are largely inter-compatible and may be employed depending on local facilities. Interestingly, the purity of the final LPC was influenced by the protein content in the initial leaf mass rather than the purification method employed. Furthermore, the amino acid composition of the LPC was dependent on the extraction method employed. In laboratory conditions, protein fractions of 96% purity could be produced with a recovery of 56% w/w and an overall yield of 5.5%. Telek on the other hand experimented with numerous tropical plants at a large scale using a combination of pulping and heat coagulation. Yields were around 3% with protein recoveries <50%. Depending on the purity of the recovered protein, they are either called leaf protein extract (<60% w/w), leaf protein concentrate (>60% w/w), or leaf protein isolate (>90% w/w), although publications use these terms interchangeably.

Sources: en.wikipedia.org

Notes from published material

In the 17th century Cossacks waged war against the Ottomans and the Crimean Khanate. In 1637 the Don Cossacks, joined by the Zaporozhian Cossacks, captured the strategic Ottoman fortress of Azov, which guarded the Don. The defense of the Azov Fortress in 1641 was one of the key actions in Don Cossack history. After total taking of the Free Territories of Don Cossacks under the Moscovy control, Don Cossack history became more intertwined with the history of the rest of Russia. In exchange for protection of the Southern borders of medieval Russia, the Don Cossacks were given the privilege of not paying taxes and the tsar's authority in Cossack lands was not as absolute as in other parts of Russia. During this period, three of Russia's most notorious rebels, Stenka Razin, Kondraty Bulavin and Emelian Pugachev, were Don Cossacks.

== Transcriptomics == Different Hydra cell types express gene families of different evolutionary ages. Progenitor cells (stem cells, neuron and nematocyst precursors, and germ cells) express genes from families that predate metazoans. Among differentiated cells some express genes from families that date from the base of metazoans, like gland and neuronal cells, and others express genes from newer families, originating from the base of cnidaria or medusozoa, like nematocysts. Interstitial cells contain translation factors with a function that has been conserved for at least 400 million years.

== History == In screening the GSK compound collection and various libraries, a key consideration was to choose a template with good levels of selectivity over the three vasopressin receptors which are structurally similar to the oxytocin receptor. In addition all templates were also assessed by in silico profiling and suitable templates were evaluated in vitro for predicted CNS penetration. This was to decrease the risk that templates would be chosen that would cross the blood brain barrier and thus block the central effects of oxytocin both in the foetus and in the mother. This identified the small, conformationally constrained, homochiral 2,5-DKP scaffold as the preferred template and lead to the success in designing and developing the highly potent and selective, orally active, peripheral oxytocin antagonist Epelsiban as a clinical candidate.

Sources: en.wikipedia.org

Frequently asked questions